Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
92.99
+1.53 (1.67%)
Pre-market: 94.16 +1.17 (1.26%)
Jul 30, 6:55AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 91.60 - 93.25
52 week 55.96 - 93.25
Open 92.10
Vol / Avg. 3,543.00/11.87M
Mkt cap 141.91B
P/E 20.89
Div/yield     -
EPS 4.45
Shares 1.53B
Beta 0.71
Inst. own 94%
Oct 27, 2014
Q3 2014 Gilead Sciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 23, 2014
Q2 2014 Gilead Sciences Inc Earnings Call - Webcast
Jul 23, 2014
Q2 2014 Gilead Sciences Earnings Release
Jun 17, 2014
Gilead Sciences at Wells Fargo Healthcare Conference
Jun 10, 2014
Gilead Sciences at Goldman Sachs Healthcare Conference
Jun 10, 2014
Gilead Sciences at William Blair & Company LLC Growth Stock Conference
May 20, 2014
Gilead Sciences at UBS Global Healthcare Conference - Webcast
May 14, 2014
Gilead Sciences at Bank of America Merrill Lynch Health Care Conference - Webcast
May 7, 2014
Gilead Sciences 2014 Annual Stockholders Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 55.86% 27.29%
Operating margin 67.53% 40.39%
EBITD margin - 43.46%
Return on average assets 49.40% 13.98%
Return on average equity 98.35% 29.75%
Employees 6,100 -
CDP Score - -

Address

333 LAKESIDE DR
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

Officers and directors

John C. Martin Ph.D. Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
John F. Milligan Ph.D. President, Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul R. Carter Executive Vice President - Commercial Operations
Age: 53
Bio & Compensation  - Reuters
John F. Cogan Jr., Ph.d. Lead Independent Director
Bio & Compensation  - Reuters
Etienne F. Davignon Independent Director
Age: 81
Bio & Compensation  - Reuters
Carla A. Hills Independent Director
Age: 80
Bio & Compensation  - Reuters
Kevin E. Lofton Independent Director
Age: 59
Bio & Compensation  - Reuters